TABLE A1.
Characteristics of Alzheimer's disease pivotal clinical trials
| Trial characteristic | Estimate |
|---|---|
| N | 314 |
| Trial phase | |
| II/III | 34 (10.8%) |
| III | 279 (88.9%) |
| III/IV | 1 (0.3%) |
| Trial start year | |
| 1997–2000 | 62 (19.1%) |
| 2001–2005 | 76 (24.2%) |
| 2006–2010 | 68 (21.7%) |
| 2011–2015 | 56 (17.8%) |
| 2016–2020 | 52 (16.6%) |
| DMT status | |
| Yes | 124 (39.5%) |
| Number of unique primary endpoints | |
| 1 | 159 (50.6%) |
| 2 | 112 (35.7%) |
| 3 | 23 (7.3%) |
| 4 | 12 (3.8%) |
| 5 | 3 (1.0%) |
| 6 | 2 (0.6%) |
| 7 | 1 (0.3%) |
| 8 | 2 (0.6%) |
| Trial region (not mutually exclusive) | |
| Americas | 187 (59.6%) |
| North America | 182 (58.0%) |
| South America | 43 (13.7%) |
| Caribbean/Central America | 13 (4.1%) |
| Europe | 150 (47.8%) |
| Eastern Europe | 75 (23.9%) |
| Asia | 100 (31.9%) |
| Australia/Oceania | 60 (19.1%) |
| Western Asia/Middle East | 25 (8.0%) |
| Africa | 0 (0.0%) |
| Not Available | 2 (0.6%) |
Abbreviation: DMT, disease‐modifying therapy.